Peter F. Lebowitz - Articles and news items

Janssen Pharmaceuticals Logo

Independent data monitoring committee recommends early stopping of Phase 3 study of Ibrutinib in relapsed/refractory CLL/SLL patients based on a planned interim analysis

Industry news / 7 January 2014 / Johnson & Johnson

“We’re delighted with this outcome, and look forward to sharing these results with the scientific community and Health Authorities…”

Janssen Pharmaceuticals Logo

Simultaneous applications submitted to FDA and EMA for siltuximab for the treatment of MCD, a rare blood disorder

Industry news, News / 3 September 2013 / Johnson & Johnson

“We’re proud of our work on siltuximab. As a rare disease with a small patient population, MCD is an area of significant unmet need”

Johnson & Johnson logo

Johnson & Johnson announces definitive agreement to acquire Aragon Pharmaceuticals, Inc.

Industry news, News / 17 June 2013 / Johnson & Johnson

Late-stage prostate cancer treatment strengthens oncology pipeline…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...